Spots Global Cancer Trial Database for til
Every month we try and update this database with for til cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma | NCT00200577 | Melanoma | TIL + IL2 | - 75 Years | Nantes University Hospital | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | NCT03215810 | Non-Small Cell ... Metastatic Non-... Squamous Cell C... Advanced NSCLC Adenosquamous C... Adenocarcinomas | Tumor-infiltrat... Nivolumab Cyclophosphamid... Fludarabine Tumor-infiltrat... Interleukin-2 (... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | NCT03166397 | Malignant Melan... | Fludarabine Cyclophosphamid... TIL IL-2 Nivolumab Ipilimumab FMT Protocol | 18 Years - 80 Years | Sheba Medical Center | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Immunotherapy for the Treatment of Advanced Solid Tumor | NCT03658785 | Recurrence Tumo... Metastatic Canc... Solid Tumor | TIL Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | Tongji Hospital | |
| Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme | NCT03347097 | Glioblastoma Mu... | TIL PD1-TIL | 18 Years - 70 Years | Huashan Hospital | |
| ITIL-168 in Advanced Melanoma | NCT05050006 | Advanced Cutane... | ITIL-168 | 18 Years - | Instil Bio | |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer | NCT03419559 | Non Small Cell ... | LN-145 Durvalumab | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | NCT03083873 | Squamous Cell C... | LN-145 LN-145-S1 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma | NCT04052334 | Sarcoma | TIL Interleukin-2 Fludarabine Cyclophosphamid... | 18 Years - 39 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| ITIL-306 in Advanced Solid Tumors | NCT05397093 | Epithelial Ovar... Non-small Cell ... Renal Cell Carc... | ITIL-306 | 18 Years - | Instil Bio | |
| ITIL-168 in Advanced Solid Tumors | NCT05393635 | Cervical Cancer Head and Neck S... Non-small Cell ... | ITIL-168 | 18 Years - | Instil Bio | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| ITIL-168 in Advanced Melanoma | NCT05050006 | Advanced Cutane... | ITIL-168 | 18 Years - | Instil Bio | |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases | NCT05903937 | Uveal Melanoma Metastatic Cuta... | Autologous Tumo... Melphalan Interleukin-2 | 18 Years - | Vastra Gotaland Region | |
| A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | NCT03903887 | Non-small Cell ... | anti-PD1 antibo... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | NCT03903887 | Non-small Cell ... | anti-PD1 antibo... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study to Investigate LYL845 in Adults With Solid Tumors | NCT05573035 | Melanoma Non-small Cell ... Colorectal Canc... | LYL845 | 18 Years - 75 Years | Lyell Immunopharma, Inc. | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | NCT05576077 | Breast Cancer Colorectal Canc... Uveal Melanoma Cutaneous Melan... Non-Small Cell ... Head and Neck S... | TBio-4101 Pembrolizumab | 18 Years - 70 Years | Turnstone Biologics, Corp. | |
| A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer | NCT03904537 | Colorectal Canc... | anti-PD-1 antib... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of DeTIL-0255 in Adults With Advanced Malignancies | NCT05107739 | Platinum-resist... Endometrial Can... Cervical Cancer | Drug Product De... | 18 Years - 70 Years | Nurix Therapeutics, Inc. | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer | NCT03419559 | Non Small Cell ... | LN-145 Durvalumab | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors | NCT03992326 | Solid Tumor, Ad... | TIL Cyclophosphamid... Fludarabine Interleukin-2 Radiotherapy | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Study to Investigate LYL845 in Adults With Solid Tumors | NCT05573035 | Melanoma Non-small Cell ... Colorectal Canc... | LYL845 | 18 Years - 75 Years | Lyell Immunopharma, Inc. | |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | NCT06060613 | Tumor Skin Metastatic Mela... Melanoma Lung Cancer Metastatic Lung... Non Small Cell ... Metastatic Non ... | OBX-115 | 18 Years - | Obsidian Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
